ホーム > 市場調査レポート > 医薬品

核酸医薬

表紙：中枢神経系特異的アンチセンスオリゴヌクレオチド市場：規模、シェア、見通し、機会分析（2022年～2028年）

市場調査レポート

商品コード

1084613

中枢神経系特異的アンチセンスオリゴヌクレオチド市場：規模、シェア、見通し、機会分析（2022年～2028年）

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月02日 | 発行: Coherent Market Insights

| ページ情報: 英文 206 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 704,385円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,095,710円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,565,300円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.53円

全表示
概要
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場について調査し、市場の概要とともに、薬剤別、適応別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.

Market Dynamics

Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.

Key features of the study:

This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Detailed Segmentation:

Global CNS Specific Antisense Oligonucleotide Market, By Drug:
- Approved
  - Patisiran
  - Nusinersen
  - Inotersen
- Pipeline
  - IONIS-HTT Rx (RG6042)
Global CNS Specific Antisense Oligonucleotide Market, By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington's Disease
Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global CNS Specific Antisense Oligonucleotide Market, By Geography:
- North America
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug:
  - Approved
  - Patisiran
  - Nusinersen
  - Inotersen
  - Pipeline
  - IONIS-HTT Rx (RG6042)
  - By Indication:
  - Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
  - Spinal Muscular Atrophy
  - Huntington's Disease
  - By Distribution Channel:
  - Hospital Pharmacy
  - Retail Pharmacy
  - Online Pharmacy
  - By Country:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- Alnylam Pharmaceuticals Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Sarepta Therapeutics Inc.
- Biogen Inc.
- Ionis Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
- Stroke Therapeutic Inc.
- Dynacure
- ProQR Therapeutics N.V.
- Q-STATE BIOSCIENCES, INC.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
Pest Analysis

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Approved
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Patisiran
- Nusinersen
- Inotersen
Pipeline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- IONIS-HTT Rx (RG6042)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Spinal Muscular Atrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Huntington's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2017 - 2028, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
North America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
Middle East
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- Alnylam Pharmaceuticals Inc.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics Inc.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biogen Inc.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ionis Pharmaceuticals Inc.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Wave Life Sciences Ltd.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Stroke Therapeutic Inc.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dynacure
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ProQR Therapeutics N.V.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Q-STATE BIOSCIENCES, INC.
- Company Overview
- Drug Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Analyst Views

9. Section

References
Research Methodology
About us and Sales Contact

ライセンス / 価格

PDF (Single User License)

USD 4,500 704,385円

PDF (Multi User License)

USD 7,000 1,095,710円

PDF (Enterprise User License)

USD 10,000 1,565,300円

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.53円

お電話でのお問い合わせ

044-952-0102

( 土日・祝日を除く )

アンチセンスオリゴヌクレオチド

中枢神経系特異的アンチセンスオリゴヌクレオチド市場：規模、シェア、見通し、機会分析（2022年～2028年）

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場の展望

第3章市場力学、規制、および動向分析

第4章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：薬剤別、2017年～2028年、（100万米ドル）

第5章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：適応別、2017年-2028年、（100万米ドル）

第6章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：流通チャネル別、2017年～2028年、（100万米ドル）

第7章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：地域別、2017年-2028年、（100万米ドル）

第8章競合情勢

第9章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2017 - 2028, (US$ Mn)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2017 - 2028, (US$ Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2017 - 2028, (US$ Mn)

8. Competitive Landscape

9. Section

中枢神経系特異的アンチセンスオリゴヌクレオチド市場：規模、シェア、見通し、機会分析（2022年～2028年）

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場の展望

第3章 市場力学、規制、および動向分析

第4章 世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：薬剤別、2017年～2028年、（100万米ドル）

第5章 世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：適応別、2017年-2028年、（100万米ドル）

第6章 世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：流通チャネル別、2017年～2028年、（100万米ドル）

第7章 世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：地域別、2017年-2028年、（100万米ドル）

第8章 競合情勢

第9章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2017 - 2028, (US$ Mn)

5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2017 - 2028, (US$ Mn)

6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2017 - 2028, (US$ Mn)

8. Competitive Landscape

9. Section

第1章調査目的・前提条件

第2章市場の展望

第3章市場力学、規制、および動向分析

第4章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：薬剤別、2017年～2028年、（100万米ドル）

第5章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：適応別、2017年-2028年、（100万米ドル）

第6章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：流通チャネル別、2017年～2028年、（100万米ドル）

第7章世界の中枢神経系特異的アンチセンスオリゴヌクレオチド市場：地域別、2017年-2028年、（100万米ドル）

第8章競合情勢

第9章セクション